MTOR and prostate carcinoma: We conclude that R26MTA1; Ptenf/f mice recapitulate key features of MTA1/mTOR signaling pathway activation-associated advanced prostate cancer and represent a useful model for exploring novel therapeutic approaches to manage advanced disease.